ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,909.03
-1.11%
Dow Jones
42,528.36
-0.42%
US Dollar vs MXN
20.33745
0.03%
Brent Oil
77.385
0.42%
Bitcoin
96,602.66
-0.31%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Pharma Equity Group A/s (0REU)

  7. Pharma Equity Group A/s (0REU) Noticias

0REU

Pharma Equity Group A/s (0REU)

Pharma Equity Group A/s
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:0REU
FechaHoraFuenteTítuloSímboloCompañía
13/12/202405:21UK RegulatoryThe Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.LSE:0REUPharma Equity Group A/s
29/11/202400:45UK RegulatoryMartin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
15/11/202401:32UK RegulatoryConsolidated Interim report 1 January – 30 September 2024LSE:0REUPharma Equity Group A/s
23/10/202403:28UK RegulatoryPharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.LSE:0REUPharma Equity Group A/s
14/10/202401:17UK RegulatoryMajor shareholder announcement - Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
14/10/202400:59UK RegulatoryManagers’ transactions LSE:0REUPharma Equity Group A/s
11/10/202401:37UK RegulatoryPharma Equity Group announces successful completion of directed issue of new sharesLSE:0REUPharma Equity Group A/s
04/10/202406:52UK RegulatoryPharma Equity Group announces issuance of new shares in a direct issueLSE:0REUPharma Equity Group A/s
04/10/202402:01UK RegulatoryRegistration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rightsLSE:0REUPharma Equity Group A/s
16/08/202401:52UK RegulatoryConsolidated Interim Report 1 January – 30 June 2024LSE:0REUPharma Equity Group A/s
16/07/202403:09UK RegulatoryThe Board of Directors' decision to issue convertible loansLSE:0REUPharma Equity Group A/s
03/06/202409:17UK RegulatoryResults of extraordinary general meeting in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
16/05/202405:35UK RegulatoryThe Board of Director's decision to issue convertible loansLSE:0REUPharma Equity Group A/s
16/05/202400:27UK RegulatoryConsolidated interim report 1 January – 31 March 2024LSE:0REUPharma Equity Group A/s
08/05/202408:16UK RegulatoryExploration of options regarding a directed capital increase at market price in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
08/05/202403:20UK RegulatoryNotice convening the extraordinary general meeting of Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
16/04/202410:29UK RegulatoryPassing of the General Meeting of Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
05/04/202404:22UK RegulatoryPharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.LSE:0REUPharma Equity Group A/s
25/03/202407:06UK RegulatoryNotice convening the annual general meeting in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
22/03/202403:00UK RegulatoryPharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009LSE:0REUPharma Equity Group A/s
21/03/202410:32UK RegulatoryCompletion of subscription of convertible loansLSE:0REUPharma Equity Group A/s
20/03/202402:58UK RegulatoryPharma Equity Group A/S - Annual Report 2023LSE:0REUPharma Equity Group A/s
05/03/202403:11UK RegulatoryPharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).LSE:0REUPharma Equity Group A/s
 Showing the most relevant articles for your search:LSE:0REU

Su Consulta Reciente

PM
XAUUSD
Gold vs US Dollar
NASDAQ
AMZN
Amazon.com
NASDAQ
MSFT
Microsoft
AMEX
SPY
SPDR S&P 500
NYSE
VZ
Verizon Communications
FX
EURUSD
Euro vs US Dollar
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
JPM
JP Morgan Chase
FX
EURMXN
Euro vs MXN
FX
USDMXN
US Dollar vs MXN
COIN
SOLUSD
Solana
USOTC
BASFY
BASF (QX)
NYSE
NKE
Nike
NYSE
CVX
Chevron
COIN
XRPUSD
Ripple
CCOM
SILVER
SILVER
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados